GSK and Bristol Myers Squibb China Announce Key Leadership Appointments: Minnie Ke and Pascal Qian Take on Pivotal Roles

Recently, there have been frequent changes in senior executives in the pharmaceuticals industry, with new adjustments to the China teams of several multinational pharmaceutical companies, drawing widespread attention from the industry. Among them, GlaxoSmithKline (GSK) and the personnel changes at Bristol-Myers Squibb are particularly noteworthy, with two seasoned pharmaceutical professionals assuming key positions.

 Yu Xiong Ke joins GSK China to head the Medical Affairs Department

GlaxoSmithKline (GSK) China Management Team7Month7Welcomes a new member on the day, Ke Yuxiong (Minnie Ke) has officially joined, serving as Vice President and Head of China Medical Affairs, effective immediately. This news was announced byGSKVice President, General Manager of China, Yu Huiming (Sherman Yu) andGSKVice President,GSKGreater China and Intercontinental (GCI) Head of Medical AffairsMark TomsAnnounce to the employees together.

Yu Xiong Ke graduated from the Genetics program at Fudan University, with over20Years of experience in the entire drug R&D industry chain, covering multiple key stages such as early research, pre-market clinical development, and post-market medical affairs.2004After graduating in her year, she embarked on a career in the pharmaceutical industry, starting as a medical advisor at Merck. She gradually accumulated experience and subsequently held positions such as the brand lead for the immunology group at Novartis China and the head of the Medical Affairs Department at Shire China.2018Since , Ke Yuxiong has shifted to the clinical development field, successively holding key positions such as Vice President of Clinical Research and Medical Affairs at Canbridge Pharma, Head of Product Development at Bristol-Myers Squibb's R&D department in China, and Head of Product Strategy at GenSci Pharmaceuticals. His extensive experience has provided him with ...GSKhas laid a solid foundation for the new role.

 Qian Jiang Appointed as General Manager of Bristol-Myers Squibb China

Following the rumors, Bristol-Myers Squibb officially confirmed that Qian Jiang (Pascal) has been appointed as the General Manager in China.

Qian Jiang graduated from the Clinical Medicine program at Shanghai Second Medical University. His career has spanned several leading multinational pharmaceutical companies, leaving a mark of deep involvement at Roche, Merck, Pfizer, Novartis, and Eli Lilly. During his tenure at these companies, he successfully led teams to launch several well-known drugs in China, including Afinitor, Sutent, Vfend, and Singulair.

2018Year6In the month, Qianjiang joined Eli Lilly, serving as the Vice President of the China Oncology Business Unit, and simultaneously became a member of the Eli Lilly China Management Committee. During his tenure, he led the team to successfully launch Alimta, Erbitux, and Tyvyt in China, facilitated the inclusion of Erbitux in the National Reimbursement Drug List (NRDL), and smoothly completed the volume-based procurement of Alimta.2021Year7In the following month, Qian Jiang left Eli Lilly and subsequently joined LianBio, holding positions such as General Manager of China and Chief Business Officer.

2023Year10In the month, Bristol-Myers Squibb obtained the exclusive development and commercialization rights for the hypertrophic cardiomyopathy product Mavacamten (Mavacamten capsules) in multiple markets from LianBio. Qian Jiang subsequently took charge of this business as the General Manager of Mavacamten, becoming a member of the Bristol-Myers Squibb China leadership team.2024Year11Last month, he was appointed as the head of commercialization for Bristol-Myers Squibb in mainland China and Hong Kong. Now promoted to General Manager of China, this pharmaceutical industry“Old Guard”Will continue to drive the localization process of innovative drugs in the new position, highly anticipated by the industry.

The appointment of these senior executives will inject new vitality into the development of relevant enterprises, and their subsequent actions are worth continuous attention from the industry.

Reference: Pharmaceutical Representative